IRIS UniCatt

Fabbiani, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.640
NA - Nord America 3.260
AS - Asia 1.252
SA - Sud America 194
AF - Africa 18
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 4
Totale 9.375
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.215
DE - Germania 1.230
IT - Italia 1.023
SE - Svezia 588
CN - Cina 510
FR - Francia 450
PL - Polonia 434
SG - Singapore 422
UA - Ucraina 327
BR - Brasile 172
GB - Regno Unito 149
IE - Irlanda 140
IN - India 97
FI - Finlandia 88
ID - Indonesia 81
NL - Olanda 59
RU - Federazione Russa 58
TR - Turchia 50
CA - Canada 33
BE - Belgio 26
HK - Hong Kong 18
IR - Iran 18
AT - Austria 9
JP - Giappone 9
ES - Italia 8
VN - Vietnam 8
AR - Argentina 7
CH - Svizzera 7
CZ - Repubblica Ceca 7
EU - Europa 6
BD - Bangladesh 5
EC - Ecuador 5
MA - Marocco 5
MX - Messico 5
PE - Perù 5
AZ - Azerbaigian 4
DK - Danimarca 4
KZ - Kazakistan 4
LT - Lituania 4
PT - Portogallo 4
ZA - Sudafrica 4
BG - Bulgaria 3
JM - Giamaica 3
KE - Kenya 3
KR - Corea 3
PH - Filippine 3
PY - Paraguay 3
RO - Romania 3
UZ - Uzbekistan 3
AL - Albania 2
AU - Australia 2
EG - Egitto 2
GR - Grecia 2
HR - Croazia 2
IL - Israele 2
IM - Isola di Man 2
LU - Lussemburgo 2
MC - Monaco 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CL - Cile 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
HN - Honduras 1
HU - Ungheria 1
IQ - Iraq 1
IS - Islanda 1
JO - Giordania 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MM - Myanmar 1
MY - Malesia 1
NG - Nigeria 1
NI - Nicaragua 1
PA - Panama 1
PK - Pakistan 1
RS - Serbia 1
TH - Thailandia 1
TN - Tunisia 1
UG - Uganda 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 9.375
Salva come PNG Salva come JPEG
Città #
Chandler 653
Kraków 426
Ashburn 280
Jacksonville 247
Rome 238
Singapore 217
San Mateo 156
Milan 140
New York 140
Dublin 138
Nanjing 135
Ann Arbor 122
Dearborn 85
Nürnberg 83
Jakarta 81
Wilmington 76
Houston 74
Lawrence 71
Cattolica 66
Woodbridge 62
Nanchang 57
Lancaster 53
Boston 50
Redmond 50
Izmir 46
Redwood City 42
Los Angeles 39
The Dalles 36
Seattle 35
Shenyang 34
Moscow 31
Verona 29
Boardman 27
Brussels 26
Bremen 25
Kunming 25
Changsha 23
Fairfield 23
Mountain View 23
Hebei 22
Munich 21
Norwalk 21
Falls Church 20
Düsseldorf 18
Ottawa 18
Shanghai 18
Beijing 17
Hong Kong 17
Leawood 17
Naples 17
University Park 17
Frankfurt am Main 15
Marseille 15
São Paulo 14
Tianjin 14
Turin 14
Augusta 13
Guangzhou 13
Hangzhou 13
Jinan 13
Fremont 12
Lauterbourg 11
Pune 11
Bari 10
Bologna 10
London 10
Washington 10
Helsinki 9
Simi Valley 9
Toronto 9
Portsmouth 8
Princeton 8
Santa Clara 8
Zhengzhou 8
Cambridge 7
Changchun 7
Chicago 7
Jiaxing 7
Roubaix 7
Bexley 6
Brooklyn 6
Busto Arsizio 6
Detroit 6
Edinburgh 6
Hefei 6
Kish 6
Padova 6
Andover 5
Brasília 5
Brescia 5
Modena 5
Rio de Janeiro 5
Vienna 5
Warsaw 5
Almaty 4
Amsterdam 4
Baku 4
Chiari 4
Costa Mesa 4
Lucca 4
Totale 4.786
Salva come PNG Salva come JPEG
Nome #
IL PRIVATO SOCIALE: UN'OPPORTUNITÀ PER I PAZIENTI E PER LE STRUTTURE SANITARIE NELL'ATTUALE CONTESTO ECONOMICO 913
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 235
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 191
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 189
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 179
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 176
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 171
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 167
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 162
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 149
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 148
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 145
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 145
Variability of raltegravir plasma levels in the clinical setting 141
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 141
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 134
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 133
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 132
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy 126
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 123
Initial antifungal strategy does not correlate with mortality in patients with candidemia 123
Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples 121
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 120
Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection 119
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 119
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 119
Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS 119
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 118
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 116
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 116
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 114
Cognitive reserve and neuropsychological functioning in older HIV-infected people 114
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 113
Effect of aging and human immunodeficiency virus infection on cognitive abilities 112
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 112
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 111
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 108
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 107
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 107
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 107
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 106
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 106
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 105
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 103
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects 102
Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model? 102
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 102
Immune response to influenza A(H1N1)v in HIV-infected patients 101
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 99
Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data 99
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 99
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 99
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 98
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 95
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 92
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 89
Lipid-lowering effect of tenofovir in HIV-infected patients 89
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 88
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis 88
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 86
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 86
Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine plus atazanavir/ritonavir (ATV/r) to abacavir/lamivudine plus ATV/r in patients with preserved renal function 85
Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area 83
Immune response to influenza A(H1N1)v in HIV-infected patients 80
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 80
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 80
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 80
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 79
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 73
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 72
Liver fibrosis progression and clinical outcomes are intertwined: Role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCVcoinfected patients with detectable HCV-RNA A MASTER cohort study 71
Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data From a Multicenter Cohort 66
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 63
Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART 59
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 55
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 53
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 52
Is there a drug-drug interaction between darunavir/ritonavir and raltegravir? 48
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received 44
Totale 9.452
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.797
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.797
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202081 0 0 0 0 0 0 0 0 0 0 0 81
2020/2021696 41 86 7 74 85 37 76 16 115 22 121 16
2021/2022806 77 64 25 61 47 40 21 129 29 73 121 119
2022/20231.639 237 261 132 258 136 191 29 145 186 11 39 14
2023/20241.021 41 231 30 106 45 212 68 22 30 50 116 70
2024/20251.698 55 55 120 103 222 89 99 160 332 154 294 15
Totale 9.452